Summary: NeoGenomics has launched AML Express, a next-generation sequencing assay that delivers rapid and comprehensive genetic profiling for acute myeloid leukemia (AML) patients, helping guide precise treatment decisions.
Takeaways:
- AML Express provides results in just 3-4 days, offering a faster and more cost-effective alternative to traditional single-gene testing for acute myeloid leukemia.
- The test covers clinically relevant DNA and RNA alterations, enhancing decision-making for clinicians and facilitating personalized treatment strategies for AML patients.
- AML Express aligns with leading clinical guidelines, supporting timely treatment initiation and potentially reducing hospital stays and improving patient outcomes.
NeoGenomics, a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML).
“AML Express enhances our hematologic portfolio by addressing the clinical need for faster testing that informs critical treatment decisions,” says Chris Smith, CEO of NeoGenomics. “This new test offers physicians a more efficient solution that delivers patient-specific insights to guide precise treatment strategies.”
Impact of Acute Myeloid Leukemia (AML)
AML accounts for about one out of three leukemias in adults. It is an aggressive disease that often develops and progresses rapidly over a few weeks, making access to timely and accurate diagnostic and prognostic information critical for patient care. With a turnaround time of just three to four days, AML Express delivers a time- and cost-effective alternative to traditional single-gene testing methods.
About the AML Express Assay
The panel includes an extensive list of genes selected for their clinical relevance in AML, covering DNA and RNA alterations, and is intended to be used in conjunction with clinical features and other laboratory results. AML Express simplifies the decision-making process for clinicians, facilitates patient enrollment in clinical trials, and supports the development of personalized treatment strategies.
“Patients with newly diagnosed acute myeloid leukemia are extremely ill at diagnosis and are at risk of life-threatening complications before initiating treatment,” says Nathan Montgomery, MD, PhD, VP of Medical Services at NeoGenomics. “AML Express will be an important tool to help patients get the right treatment sooner, which we believe will reduce the length of hospital stays and improve patient outcomes.”
AML Express aligns with the latest guidelines from the European LeukemiaNet, adopted by the National Comprehensive Cancer Network (NCCN), and the World Health Organization Classification for Hematolymphoid Tumors (5th edition). The new panel expands NeoGenomics’ broad hematology portfolio, which includes Neo Comprehensive NGS tests, COMPASS, and other key assays.
Further reading: NeoGenomics Assay for MRD and Breast Cancer Recurrence Gets Medicare Coverage
